Karuna Therapeutics Inc. (KRTX) PT Raised to $148 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Karuna Therapeutics Inc. (KRTX) Prices 2.08M Share Common Offering at $120/Sh
March 2, 2021 6:08 AM ESTKaruna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share. The gross proceeds to Karuna from the... More
Karuna Therapeutics Inc. (KRTX) PT Raised to $165 at RBC Capital, Sees Underappreciated De-Risking
March 1, 2021 6:50 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $165.00 (from $160.00) while maintaining a Outperform rating.
The analyst comments "Late last week, KRTX reported preliminary qualitative data from its ph.Ib study of lead drug KarXT in... More
